In October, Dr Nazia Chaudhuri presented the first of a two-part Let’s Talk series on the importance of Clinical Trials in Interstitial Lung Diseases (ILDs). This first session provided an overview of the clinical trial process, considerations when participating, and what to expect when engaging in a clinical trial. Following on our Part I clinical trials overview session with Dr Nazia Chaudhuri, Part II of our Let’s Talk Clinical Trials session held in November focused on the Irish context featuring Cormac McCarthy discussing current and upcoming clinical trials in Ireland. Both sessions were facilitated by ILFA Board Member, Colin Edwards.
Link to Part I with Nazia Chaudhuri: https://youtu.be/ECfTY4LpBZk
Link to Part II with Cormac McCarthy: https://youtu.be/nx1cGW0wRU0
About our Presenters:
Dr Nazia Chaudhuri is a Senior Clinical Lecturer at the Ulster University School of Medicine and a Respiratory Physician with expertise in Interstitial Lung Disease (ILD) at Altnagelvin Hospital in Derry. She chairs the NI Respiratory Forum, is Secretary of the Irish Thoracic Society (ITS) and European Respiratory Society (ERS) ILD Societies.
Professor Cormac McCarthy is a Consultant Respiratory Physician at St Vincent’s University Hospital and Associate Professor of Medicine at University College Dublin. He is Director of the UCD Lung Centre and Director of the Academic Centre for Rare Diseases at UCD. His clinical and translational research interests focus on interstitial lung diseases, pulmonary alveolar proteinosis, and diffuse cystic lung diseases, with a particular emphasis on biomarker discovery, disease mechanisms, and translational therapeutics. His work integrates mechanistic science with clinical research and clinical trials to advance diagnostics, treatment strategies, and patient outcomes in rare and complex respiratory diseases.
Colin Edwards is the founder of MerlinConsulting and a co-founder of patientMpower, an Irish digital
health company focused on lung and kidney health. Colin retired from patientMpower in 2022 but continues as an advisor and board member. He currently serves on the boards of the Irish Lung Fibrosis Association and Siel Bleu Ireland.